# Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

> **NCT02523768** · PHASE4 · TERMINATED · sponsor: **Centre Hospitalier Universitaire de Saint Etienne** · enrollment: 117 (actual)

## Conditions studied

- Glomerulonephritis
- IgAN

## Interventions

- **DRUG:** ATG-F
- **DRUG:** Simulect

## Key facts

- **NCT ID:** NCT02523768
- **Lead sponsor:** Centre Hospitalier Universitaire de Saint Etienne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01-08
- **Primary completion:** 2020-01-24
- **Final completion:** 2020-02-24
- **Target enrollment:** 117 (ACTUAL)
- **Why stopped:** Difficulties for recruting patients
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02523768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02523768, "Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02523768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*